Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 9/20 | 0.32 |
| ▸ | AXL | P30530 | 4/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596416 | 0.86 | NOTUM (0.37) | NOTUMDRD2GRM5TAAR1MEN1 | |
| SCHEMBL5596331 | 0.86 | ROCK2 (0.38) | NOTUMDRD2TAAR1 | |
| SCHEMBL5596755 | 0.81 | NOTUM (0.32) | NOTUMALDH1A1 | |
| SCHEMBL5596700 | 0.81 | GRIN2B (0.41) | MEN1KMT2A | |
| SCHEMBL5596709 | 0.79 | NOTUM (0.36) | NOTUM | |
| SCHEMBL5421579 | 0.79 | GPBAR1 (0.36) | MEN1ALOX15KMT2A | |
| SCHEMBL5597050 | 0.78 | DRD2 (0.35) | DRD2MERTKAXLTYRO3MEN1 | |
| SCHEMBL5596271 | 0.78 | DRD2 (0.35) | NOTUMDRD2MERTKAXLTYRO3 | |
| SCHEMBL5419864 | 0.77 | ADRA1B (0.42) | DRD2ALDH1A1 | |
| SCHEMBL5596409 | 0.76 | GPR119 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | NOTUM 4510/4885DRD2 1473/4885MERTK 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.